OPK · Company research
Opko Health Inc. (OPK): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
49records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| OPKO Health to Sell Select BioReference Assets to Labcorp for $722M | OPKO Health announced an agreement to sell select BioReference assets to Labcorp for $722 million in cash plus up to $150 million in earnouts. The deal includes the 4Kscore Test, specialty testing operations, and over 80 patient service centers. OPKO aims to focus on its biopharmaceutical business, while Labcorp expects $250 million in first-year revenue from the acquisition. OPK stock rose 17.5% following the announcement. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| OPKO Health to Sell Select BioReference Assets to Labcorp for $722M - TradingView | OPKO Health to Sell Select BioReference Assets to Labcorp for $722M TradingView | View source ↗ | TradingView | Oct 16, 2026 | neutral | 0 | 0.6 |
| OPKO Health (NASDAQ:OPK) Stock Rating Raised to Outperform at Barrington Research - MarketBeat | OPKO Health (NASDAQ:OPK) Stock Rating Raised to Outperform at Barrington Research MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| OPK Stock Slides As Traders Track Support Levels - StocksToTrade | OPK Stock Slides As Traders Track Support Levels StocksToTrade | View source ↗ | StocksToTrade | Oct 15, 2026 | neutral | 0 | 0.6 |
| BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients | Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization. The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients | Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization. The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| OPKO Health (NASDAQ:OPK) Shares Gap Up - What's Next? - MarketBeat | OPKO Health (NASDAQ:OPK) Shares Gap Up - What's Next? MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| Doximity Deepens U.S. News Alliance to Improve Patient Access to Care | Doximity announced an extension of its 13-year partnership with U.S. News & World Report, continuing to provide physician data for Doctor Finder, Patient Connect appointment-booking tools, and Expert Opinion surveys for hospital rankings. The partnership leverages Doximity's network of 3+ million medical professionals to connect patients with healthcare providers. Despite the news, DOCS stock declined 2.1% following the announcement and is down 32.4% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| Doximity Deepens U.S. News Alliance to Improve Patient Access to Care | Doximity announced an extension of its 13-year partnership with U.S. News & World Report, continuing to provide physician data for Doctor Finder, Patient Connect appointment-booking tools, and Expert Opinion surveys for hospital rankings. The partnership leverages Doximity's network of 3+ million medical professionals to connect patients with healthcare providers. Despite the news, DOCS stock declined 2.1% following the announcement and is down 32.4% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| OPK Stock Slides As Charts Flash Potential Pivot Zone - Timothy Sykes | OPK Stock Slides As Charts Flash Potential Pivot Zone Timothy Sykes | View source ↗ | Timothy Sykes | Oct 15, 2026 | neutral | 0 | 0.6 |
| OPK Stock Holds Support As Traders Gauge Turnaround Odds - StocksToTrade | OPK Stock Holds Support As Traders Gauge Turnaround Odds StocksToTrade | View source ↗ | StocksToTrade | Oct 15, 2026 | neutral | 0 | 0.6 |
| OPK Stock Slides As Traders Weigh Weak Cash Flow And Support Levels - Timothy Sykes | OPK Stock Slides As Traders Weigh Weak Cash Flow And Support Levels Timothy Sykes | View source ↗ | Timothy Sykes | Oct 15, 2026 | neutral | 0 | 0.6 |
| OPK Stock Grinds Lower As Traders Focus On Cash And Charts - Timothy Sykes | OPK Stock Grinds Lower As Traders Focus On Cash And Charts Timothy Sykes | View source ↗ | Timothy Sykes | Oct 15, 2026 | neutral | 0 | 0.6 |
| Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? | Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? | BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business. However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? | BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business. However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Reasons to Add QuidelOrtho Stock to Your Portfolio for Now | QuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Reasons to Add QuidelOrtho Stock to Your Portfolio for Now | QuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Hims & Hers Expands Australian Women's Health Platform With Hers | Hims & Hers Health has launched Hers, its women's health platform, in Australia by rebranding Juniper from its Eucalyptus acquisition. The platform offers personalized care for hair regrowth, menopause, and weight management with 24/7 support. The expansion leverages Eucalyptus' local presence to strengthen brand recognition and recurring revenue in the growing Australian telehealth market, which is projected to grow at 18.2% CAGR through 2034. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.75 | 1 |
| Hims & Hers Expands Australian Women's Health Platform With Hers | Hims & Hers Health has launched Hers, its women's health platform, in Australia by rebranding Juniper from its Eucalyptus acquisition. The platform offers personalized care for hair regrowth, menopause, and weight management with 24/7 support. The expansion leverages Eucalyptus' local presence to strengthen brand recognition and recurring revenue in the growing Australian telehealth market, which is projected to grow at 18.2% CAGR through 2034. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.75 | 1 |
| Here's Why You Should Add Avantor Stock to Your Portfolio for Now | Avantor (AVTR) reported strong second-quarter 2026 results with raised 2026 guidance, driven by VWR segment's return to 1.7% organic growth and BMP's double-digit order growth. However, BMP's continued 5.6% organic revenue decline and uneven demand recovery remain concerns. The company's Revival program shows execution improvements across commercial performance and operations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Here's Why You Should Add Avantor Stock to Your Portfolio for Now | Avantor (AVTR) reported strong second-quarter 2026 results with raised 2026 guidance, driven by VWR segment's return to 1.7% organic growth and BMP's double-digit order growth. However, BMP's continued 5.6% organic revenue decline and uneven demand recovery remain concerns. The company's Revival program shows execution improvements across commercial performance and operations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| OPKO Health, Inc. (OPK) Stock Price, News, Quote & History - Yahoo! Finance Canada | OPKO Health, Inc. (OPK) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Retain AMN Stock in Your Portfolio for Now | AMN Healthcare is positioned for growth driven by rising healthcare staffing demand, technology investments, and higher-margin services, with Nurse and Allied revenues up 11% and Passport users growing 33%. However, persistent pricing competition, weakness in physician and technology segments, and earnings normalization pose significant headwinds to sustained performance. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.75 | 1 |
| OPKO Health (OPK) Short Interest & Short Float | Updated Oct 2026 $OPK - MarketBeat | OPKO Health (OPK) Short Interest & Short Float | Updated Oct 2026 $OPK MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Bruker Gains 66.3% in a Year: What's Driving the Rally? | Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Bruker Gains 66.3% in a Year: What's Driving the Rally? | Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Bruker Gains 66.3% in a Year: What's Driving the Rally? | Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Here's Why You Should Retain WAT Stock in Your Portfolio for Now | Waters Corporation (WAT) is positioned for growth driven by sustained analytical sciences demand, BD acquisition integration, and product innovation. The company projects 10.9% year-over-year earnings growth for 2026 with $50 million in revenue synergies and $75 million in cost savings expected. However, weakness in China diagnostics, BD integration execution risks, and dependence on customer capital spending present headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Here's Why You Should Retain WAT Stock in Your Portfolio for Now | Waters Corporation (WAT) is positioned for growth driven by sustained analytical sciences demand, BD acquisition integration, and product innovation. The company projects 10.9% year-over-year earnings growth for 2026 with $50 million in revenue synergies and $75 million in cost savings expected. However, weakness in China diagnostics, BD integration execution risks, and dependence on customer capital spending present headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Here's Why You Should Retain WAT Stock in Your Portfolio for Now | Waters Corporation (WAT) is positioned for growth driven by sustained analytical sciences demand, BD acquisition integration, and product innovation. The company projects 10.9% year-over-year earnings growth for 2026 with $50 million in revenue synergies and $75 million in cost savings expected. However, weakness in China diagnostics, BD integration execution risks, and dependence on customer capital spending present headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment | Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment | Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Reasons to Add Globus Medical Stock to Your Portfolio Now | Globus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway. However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Reasons to Add Globus Medical Stock to Your Portfolio Now | Globus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway. However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| OPKO Health (NasdaqGS:OPK) Stock Forecast & Analyst Predictions - Simply Wall Street | OPKO Health (NasdaqGS:OPK) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| OPKO Health, Inc. (NASDAQ:OPK) Stock Now Rated "Hold" by Sell-Side Analysts - MarketBeat | OPKO Health, Inc. (NASDAQ:OPK) Stock Now Rated "Hold" by Sell-Side Analysts MarketBeat | View source ↗ | MarketBeat | Oct 3, 2026 | neutral | 0 | 0.6 |
| OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by Zacks Research - MarketBeat | OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by Zacks Research MarketBeat | View source ↗ | MarketBeat | Sep 30, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Retain OPK Stock in Your Portfolio for Now - Yahoo Finance | Here's Why You Should Retain OPK Stock in Your Portfolio for Now Yahoo Finance | View source ↗ | Yahoo Finance | Sep 28, 2026 | neutral | 0 | 0.6 |
| OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026? - Yahoo Finance | OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 21, 2026 | neutral | 0 | 0.6 |
| A healthcare conference will feature two OPKO executives on Sept. 10 - Stock Titan | A healthcare conference will feature two OPKO executives on Sept. 10 Stock Titan | View source ↗ | Stock Titan | Sep 8, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Retain OPK Stock in Your Portfolio for Now - Zacks Investment Research | Here's Why You Should Retain OPK Stock in Your Portfolio for Now Zacks Investment Research | View source ↗ | Zacks Investment Research | Aug 24, 2026 | neutral | 0 | 0.6 |
| OPKO Health (OPK) Stock Jumps As Losses Shrink And Pipeline Progress Builds - Simply Wall Street | OPKO Health (OPK) Stock Jumps As Losses Shrink And Pipeline Progress Builds Simply Wall Street | View source ↗ | Simply Wall Street | Jul 28, 2026 | neutral | 0 | 0.6 |
| OPKO HEALTH ($OPK) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative | OPKO HEALTH ($OPK) Releases Q2 2026 Earnings, Stock Rises Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 27, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Retain OPK Stock in Your Portfolio for Now - TradingView | Here's Why You Should Retain OPK Stock in Your Portfolio for Now TradingView | View source ↗ | TradingView | Jul 23, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Hold OPK Stock in Your Portfolio for Now - Yahoo Finance | Here's Why You Should Hold OPK Stock in Your Portfolio for Now Yahoo Finance | View source ↗ | Yahoo Finance | Mar 19, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.